RVL Pharmaceuticals plc, formely known as Osmotica Pharmaceutical plc, is focused on the commercialization of osmotic drug delivery technologies.In August 2021, Osmotica Pharmaceuticals plc announced that it has closed the previously announced sale of its legacy business to Alora Pharmaceuticals, LLC.In October 2017, the company entered into a stock purchase agreement with Nephron Pharmaceuticals Corporation, Point Guard Partners, LLC, VOOM LLC, Tom Riedhammer, Avery Family Trust, and Vision Quest Holdings, LLC (collectively, the "Sellers") to purchase the outstanding stock of RevitaLid. The company obtained all rights to the VOOM LLC license agreement and would be undertaking future development and commercialization of RVL-1201.In February 2016, Osmotica and Trigen Holdings completed the merger and created a combined company named Osmotica.In February 2021, Adamas Pharmaceuticals closed the settlement of patent litigation with Osmotica Pharmaceuticals plc.In Septem